Search Results - Mark Middleton

  • Showing 1 - 9 results of 9
Refine Results
  1. 1

    The role of circulating tumor DNA in melanomas of the uveal tract by Mohammed Zeeshan Zameer, Eric Jou, Eric Jou, Mark Middleton

    Published in Frontiers in Immunology (2024-12-01)
    Get full text
    Article


  2. 2

    Clinical trial protocol for PanDox: a phase I study of targeted chemotherapy delivery to non-resectable primary pancreatic tumours using thermosensitive liposomal doxorubicin (Ther... by Laura Spiers, Michael Gray, Paul Lyon, Shivan Sivakumar, Noor Bekkali, Shaun Scott, Linda Collins, Robert Carlisle, Feng Wu, Mark Middleton, Constantin Coussios

    Published in BMC Cancer (2023-09-01)
    Get full text
    Article


  3. 3

    Pseudotime dynamics of T cells in pancreatic ductal adenocarcinoma inform distinct functional states within the regulatory and cytotoxic T cells by Ashwin Jainarayanan, Nithishwer Mouroug-Anand, Edward H. Arbe-Barnes, Adam J. Bush, Rachael Bashford-Rogers, Adam Frampton, Lara Heij, Mark Middleton, Michael L. Dustin, Enas Abu-Shah, Shivan Sivakumar

    Published in iScience (2023-04-01)
    Get full text
    Article


  4. 4

    Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service. by Angela Hamblin, Sarah Wordsworth, Jilles M Fermont, Suzanne Page, Kulvinder Kaur, Carme Camps, Pamela Kaisaki, Avinash Gupta, Denis Talbot, Mark Middleton, Shirley Henderson, Anthony Cutts, Dimitrios V Vavoulis, Nick Housby, Ian Tomlinson, Jenny C Taylor, Anna Schuh

    Published in PLoS Medicine (2017-02-01)
    Get full text
    Article


  5. 5

    Evaluation of a non-animal toolbox informed by adverse outcome pathways for human inhalation safety by Renato Ivan de Ávila, Iris Müller, Hugh Barlow, Alistair Mark Middleton, Mathura Theiventhran, Danilo Basili, Anthony M. Bowden, Ouarda Saib, Patrik Engi, Tymoteusz Pietrenko, Joanne Wallace, Bernadett Boda, Samuel Constant, Holger Peter Behrsing, Vivek Patel, Maria Teresa Baltazar

    Published in Frontiers in Toxicology (2025-02-01)
    Get full text
    Article


  6. 6

    Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer by Melinda L. Telli, Sara M. Tolaney, Geoffrey I. Shapiro, Mark Middleton, Simon R. Lord, Hendrik Tobias Arkenau, Andrew Tutt, Vandana Abramson, Emma Dean, Tufia C. Haddad, Robert Wesolowski, Jordi Ferrer-Playan, Thomas Goddemeier, Thomas Grombacher, Jennifer Dong, Patricia Fleuranceau-Morel, Ivan Diaz-Padilla, Ruth Plummer

    Published in npj Breast Cancer (2022-04-01)
    Get full text
    Article


  7. 7

    506 IGNYTE: an open-label, multicenter, phase 1/2 (Ph 1/2) clinical trial of RP1 ± nivolumab in patients with advanced solid tumors by Anna Olsson-Brown, Joseph Sacco, Mark Middleton, Jason Chesney, Mohammed Milhem, Kevin Harrington, Robert Coffin, Katy Tsai, Adel Samson, Bartosz Chmielowski, Ari VanderWalde, Andrea Pirzkall, Jiaxin Niu, Praveen Bommareddy, Georgia Beasley, Gino In, Terence Rhodes, Francesca Aroldi, Lavita Menezes, Tawnya Bowles, Hamid Emamekhoo, Scott Baum, Sophie Dalac-Rat, Katharina Kahler, Eva Muñoz

    Published in Journal for ImmunoTherapy of Cancer (2021-11-01)
    Article


  8. 8

    Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease by Bart Neyns, Mark Middleton, Aurélien Marabelle, Ignacio Melero, Ke Liu, Nina Bhardwaj, Tanja D de Gruijl, Jason Chesney, Robert Coffin, Howard Kaufman, Diwakar Davar, Jason J Luke, Georgina V Long, Kevin J Harrington, Sherene Loi, Thierry de Baere, David J Pinato, Matthew Fury, Ciara M Kelly, Joshua D Brody, Robert H Andtbacka, Gregory Goldmacher, Anuradha D Khilnani, Rahul A Sheth, Stephen B Solomon, Philippe Szapary

    Published in Journal for ImmunoTherapy of Cancer (2024-04-01)
    Get full text
    Article


  9. 9

    A population-scale temporal case–control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP) by Thomas Starkey, Maria C. Ionescu, Michael Tilby, Martin Little, Emma Burke, Matthew W. Fittall, Sam Khan, Justin K. H. Liu, James R. Platt, Rosie Mew, Arvind R. Tripathy, Isabella Watts, Sophie Therese Williams, Nathan Appanna, Youssra Al-Hajji, Matthew Barnard, Liza Benny, Alexander Burnett, Jola Bytyci, Emma L. Cattell, Vinton Cheng, James J. Clark, Leonie Eastlake, Kate Gerrand, Qamar Ghafoor, Simon Grumett, Catherine Harper-Wynne, Rachel Kahn, Alvin J. X. Lee, Oliver Lomas, Anna Lydon, Hayley Mckenzie, NCRI Consumer Forum, Hari Panneerselvam, Jennifer S. Pascoe, Grisma Patel, Vijay Patel, Vanessa A. Potter, Amelia Randle, Anne S. Rigg, Tim M. Robinson, Rebecca Roylance, Tom W. Roques, Stefan Rozmanowski, René L. Roux, Ketan Shah, Remarez Sheehan, Martin Sintler, Sanskriti Swarup, Harriet Taylor, Tania Tillett, Mark Tuthill, Sarah Williams, Yuxin Ying, Andrew Beggs, Tim Iveson, Siow Ming Lee, Gary Middleton, Mark Middleton, Andrew Protheroe, Tom Fowler, Peter Johnson, Lennard Y. W. Lee

    Published in Scientific Reports (2023-07-01)
    Get full text
    Article


Search Tools: